HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
Huagongshe Open Program:[email protected]AI access: llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.7.9
  1. Home
  2. /Compound

Unii-rlm74T3Z9D

HCID 6435809
New noteNew reactionRequest quotesPrint preview
Basic informationOverviewNames & identifiersPropertiesChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
131069-91-5
Standard SMILES
COCCNC(=O)CN(CCN(CCN(CC(=O)[O-])CC(=O)NCCOC)CC(=O)[O-])CC(=O)[O-].[Gd+3]
InChIKey
HBEAOBRDTOXWRZ-UHFFFAOYSA-K
Molecular formula
C20H34GdN5O10
Average molar mass
661.8 g/mol
Monoisotopic mass
662.15468

Overview

Gadoversetamide, marketed under the trade name OptiMARK, is a gadolinium compound used as a contrast agent in magnetic resonance imaging (MRI), particularly imaging of the brain, spine and liver.

Names & identifiers

Preferred name
Unii-rlm74T3Z9D
IUPAC
2-[bis[2-[carboxylatomethyl-[2-(2-methoxyethylamino)-2-oxoethyl]amino]ethyl]amino]acetate;gadolinium(3+)

Names & synonyms

UNII-RLM74T3Z9DHSDB 7550Gadoversetamide [USAN:USP:INN:BAN]orb3134453HY-A0196(Gadoversetamide) (8,11-bis(carboxymethyl)-14-(2-((2-methoxyethyl)amino)-2-oxoethyl)-6-oxo-2-oxa-5,8,11,14-tetraazahexadecan-16-oato(3-)), gadoliniumCS-0017542{8,11-Bis[(carboxylato-kappaO)methyl]-14-{2-[(2-methoxyethyl)amino]-2-(oxo-kappaO)ethyl}-6-(oxo-kappaO)-2-oxa-5,8,11,14-tetraazahexadecan-16-oato-kappa~4~N~8~,N~11~,N~14~,O~16~}gadolinium

Database identifiers

CAS
131069-91-5
PubChem CID
6435809
DTXSID
DTXSID10156865

Properties

Computed structural properties

Topological polar surface area
207 Ų
Hydrogen bond donors
2
Hydrogen bond acceptors
13
Rotatable bonds
6
Heavy atoms
36
Formal charge
0
Complexity
637

Chemistry & industry

Pharmacology

Mechanism of Action · 1 item

Based on the behavior of protons when placed in a strong magnetic field, which is interpreted and transformed into images by magnetic resonance (MR) instruments. MR images are based primarily on proton density and proton relaxation dynamics. MR instruments are sensitive to two different relaxation processes, the T1 (spin-lattice or longitudinal relaxation time) and T2 (spin-spin or transverse relaxation time). Paramagnetic agents contain one or more unpaired electrons that enhance the T1 and T2 relaxation rates of protons in their molecular environment. In MRI, visualization of normal and pathological brain, spinal and hepatic tissue depends in part on variations in the radio frequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in T2. When placed in a magnetic field, gadoversetamide shortens the T1 and T2 relaxation times in tissues where it accumulates. At the recommended dose, the effect is primarily on T1 relaxation time, and produces an increase in signal intensity (brightness). Gadoversetamide does not cross the intact blood-brain barrier; therefore, it does not accumulate in normal brain tissue or in CNS lesions that may have a normal blood-brain barrier (e.g., cysts, mature post-operative scars). Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadoversetamide in lesions such as neoplasms, abscesses, and subacute infarcts.

Biological Half-LifeDistribution 13.3 ± 6.8 (mean) minutes, elimination 103.6 ± 19.5 (mean) minutes.
Metabolism/MetabolitesNone detected
Absorption, Distribution and Excretion · 3 items

The mean cumulative urinary excretion of gadoversetamide at 72 hours was approximately 93.5% for renal impaired patients and 95.8% for subjects with normal renal function

162 ± 25 mL/kg [normal subjects]

72 +/- 16.3 mL/hr/kg [healthy]

Suppliers

Loading…

Open inquiries

Loading…

Related reactions

0 records
New reaction record

No reaction records under the current filter.

Compound notes

Loading…

On this pageBasic informationOverviewNames & identifiersPropertiesChemistry & industryRelated reactionsCompound notes